Group One Trading
NTLA icon

Group One Trading’s Intellia Therapeutics NTLA Stock Holding History

Group One Trading’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.86M Buy
300,900
+2,100
+0.7% +$26.8K 0.01% 1511
2025
Q4 		$2.69M Buy
298,800
+93,200
+45% +$1.28M ﹤0.01% 2019
2025
Q3 		$3.55M Buy
205,600
+31,900
+18% +$393K 0.01% 1789
2025
Q2 		$1.63M Buy
173,700
+50,300
+41% +$413K ﹤0.01% 2328
2025
Q1 		$877K Buy
123,400
+63,000
+104% +$636K ﹤0.01% 2576
2024
Q4 		$704K Buy
60,400
+4,500
+8% +$70.2K ﹤0.01% 2892
2024
Q3 		$1.15M Buy
55,900
+16,400
+42% +$378K ﹤0.01% 2181
2024
Q2 		$884K Sell
39,500
-11,100
-22% -$264K ﹤0.01% 2091
2024
Q1 		$1.39M Buy
50,600
+11,400
+29% +$317K 0.01% 1801
2023
Q4 		$1.2M Buy
39,200
+14,400
+58% +$414K ﹤0.01% 2306
2023
Q3 		$784K Sell
24,800
-2,000
-7% -$77.6K ﹤0.01% 2501
2023
Q2 		$1.09M Sell
26,800
-45,500
-63% -$1.85M ﹤0.01% 2279
2023
Q1 		$2.69M Sell
72,300
-58,800
-45% -$2.31M 0.01% 1291
2022
Q4 		$4.57M Buy
131,100
+27,600
+27% +$1.31M 0.01% 1202
2022
Q3 		$5.79M Buy
103,500
+51,100
+98% +$3.17M 0.01% 1056
2022
Q2 		$2.71M Buy
52,400
+16,800
+47% +$853K ﹤0.01% 1776
2022
Q1 		$2.59M Sell
35,600
-8,500
-19% -$720K ﹤0.01% 2142
2021
Q4 		$5.21M Sell
44,100
-3,900
-8% -$489K ﹤0.01% 1670
2021
Q3 		$6.44M Sell
48,000
-118,900
-71% -$18M 0.01% 1450
2021
Q2 		$27M Buy
166,900
+77,700
+87% +$6.05M 0.03% 474
2021
Q1 		$7.16M Buy
89,200
+82,000
+1,139% +$5.5M 0.01% 1209
2020
Q4 		$392K Sell
7,200
-16,100
-69% -$585K ﹤0.01% 3490
2020
Q3 		$463K Sell
23,300
-15,100
-39% -$315K ﹤0.01% 2912
2020
Q2 		$807K Buy
38,400
+23,400
+156% +$398K ﹤0.01% 2226
2020
Q1 		$183K Sell
15,000
-14,000
-48% -$189K ﹤0.01% 2827
2019
Q4 		$425K Buy
29,000
+14,800
+104% +$206K ﹤0.01% 2570
2019
Q3 		$190K Buy
14,200
+500
+4% +$7.97K ﹤0.01% 3116
2019
Q2 		$224K Sell
13,700
-13,700
-50% -$215K ﹤0.01% 2770
2019
Q1 		$468K Sell
27,400
-500
-2% -$7.45K 0.01% 2000
2018
Q4 		$381K Buy
27,900
+17,600
+171% +$327K ﹤0.01% 2182
2018
Q3 		$295K Sell
10,300
-26,800
-72% -$780K ﹤0.01% 2715
2018
Q2 		$1.01M Buy
37,100
+18,200
+96% +$441K 0.01% 1709
2018
Q1 		$399K Sell
18,900
-22,200
-54% -$546K ﹤0.01% 2229
2017
Q4 		$790K Buy
41,100
+38,000
+1,226% +$877K 0.01% 1897
2017
Q3 		$77K Buy
3,100
+2,700
+675% +$50.9K ﹤0.01% 3394
2017
Q2 		$6K Sell
400
-8,300
-95% -$116K ﹤0.01% 4370
2017
Q1 		$123K Buy
+8,700
New +$117K ﹤0.01% 2836

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Group One Trading's NTLA Position: Q1 2026 in Review

Group One Trading reduced its Intellia Therapeutics (NTLA) stake by 0.7% in Q1 2026, selling an estimated $8.1K and leaving 90,049 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2577.

Group One Trading first reported a position in NTLA in Q1 2017 and has held it in 29 quarters since. The position peaked at $4.57M in Q2 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Group One Trading held 90,049 shares of Intellia Therapeutics worth $1.15M as of Q1 2026.
  • Group One Trading sold 636 Intellia Therapeutics shares in Q1 2026, an estimated $8.1K.
  • Intellia Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #2577 holding.
  • Group One Trading first reported a position in Intellia Therapeutics in Q1 2017 and has held it in 29 quarters since.
  • Group One Trading's Intellia Therapeutics position peaked at $4.57M in Q2 2021.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.